Table 2: Clinical and pathological characteristics of study cohort depending on the presence of biochemical recurrence.

No recurrenceRecurrenceP

Number of patients, (%)173 (70.9)71 (29.1)
Age (years), mean ± std, IQR66.3 ± 6.56, 965.9 ± 6.36, 110.527
PSA (ng/mL), mean ± std, IQR8.37 ± 3.23, 4.299.99 ± 4.35, 5.200.005†*
PSA density (ng/mL2), mean ± std, IQR0.29 ± 0.25, 0.180.46 ± 0.57, 0.270.002†*
Preoperative Gleason score, n (%)0.015‡*
≤671 (41.0)16 (22.5)
779 (45.7)39 (54.9)
≥823 (13.3)16 (22.5)
Pathological Gleason score, n (%)0.423
≤665 (37.6)21 (29.6)
778 (45.1)34 (47.9)
≥830 (17.3)16 (22.5)
Clinical stage, n (%) 0.201
T1c134 (77.5)47 (66.2)
T2a29 (16.8)16 (22.5)
T2b8 (4.6)8 (11.3)
T2c2 (1.2)0 (0)
Pathological stage, n (%) 0.001‡*
T2a19 (11.0)6 (8.45)
T2b7 (4.05)1 (1.41)
T2c104 (60.1)38 (53.5)
T3a36 (20.8)11 (15.5)
T3b7 (4.05)15 (21.1)
Extracapsular disease, n (%)0.064
No130 (75.1)45 (63.4)
Yes43 (24.9)26 (36.6)
Surgical margins, n (%)0.021‡*
Negative126 (72.8)41 (57.7)
Positive47 (27.2)30 (42.3)
Seminal vesicles invasion, n (%)<0.001‡*
No166 (96.0)56 (78.9)
Yes7 (4.05)15 (21.1)
Lymph nodes invasion, n (%)<0.001‡*
No83 (100.0)39 (55.7)
Yes0 (0)31 (44.3)

Mann-Whitney U test, chi-square test, *statistically significant, std: standard deviation, and IQR: interquartile range.